During the last session, Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares were 0.41 million, with the beta value of the company hitting 0.86. At the end of the trading day, the stock’s price was $4.88, reflecting an intraday loss of -0.81% or -$0.04. The 52-week high for the CRVS share is $10.00, that puts it down -104.92 from that peak though still a striking 73.36% gain since the share price plummeted to a 52-week low of $1.30. The company’s market capitalization is $313.58M, and the average intraday trading volume over the past 10 days was 0.39 million shares, and the average trade volume was 969.40K shares over the past three months.
Corvus Pharmaceuticals Inc (CRVS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CRVS has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Corvus Pharmaceuticals Inc (CRVS) registered a -0.81% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.81% in intraday trading to $4.88, hitting a weekly high. The stock’s 5-day price performance is -6.33%, and it has moved by -0.81% in 30 days. Based on these gigs, the overall price performance for the year is 118.83%. The short interest in Corvus Pharmaceuticals Inc (NASDAQ:CRVS) is 6.11 million shares and it means that shorts have 11.01 day(s) to cover.
The consensus price target of analysts on Wall Street is $12.5, which implies an increase of 60.96% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $13 respectively. As a result, CRVS is trading at a discount of -166.39% off the target high and -145.9% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 19.89%. While earnings are projected to return -64.58% in 2025, the next five years will return -2.42% per annum.
CRVS Dividends
Corvus Pharmaceuticals Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
Corvus Pharmaceuticals Inc insiders own 4.08% of total outstanding shares while institutional holders control 48.89%, with the float percentage being 50.97%. ORBIMED ADVISORS LLC is the largest shareholder of the company, while 83.0 institutions own stock in it. As of 2024-06-30, the company held over 6.94 million shares (or 11.6289% of all shares), a total value of $12.64 million in shares.
The next largest institutional holding, with 6.12 million shares, is of SAMLYN CAPITAL, LLC’s that is approximately 10.2546% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.14 million.
Also, the Mutual Funds coming in first place with the largest holdings of Corvus Pharmaceuticals Inc (CRVS) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.58 shares. This amounts to just over 2.46 percent of the company’s overall shares, with a $7.72 million market value. The same data shows that the other fund manager holds slightly less at 767.02, or about 1.19% of the stock, which is worth about $3.74 million.
